Allogene Therapeutics Inc. (NASDAQ: ALLO) published preclinical data for ALLO-329, an investigational allogeneic CAR T therapy targeting both CD19 and CD70 for autoimmune diseases, in Nature Communications.

The study showed that ALLO-329 rapidly eliminated B and T cells in systemic lupus erythematosus models and halted autoantibody production. The therapy targets CD19+ B cells and CD70+ activated T cells, which are involved in autoimmune disease development.

According to the research, the dual-targeting approach demonstrated enhanced CAR T cell activity and persistence while potentially reducing the need for cytotoxic lymphodepletion, a pre-treatment that removes immune cells. The therapy incorporates Allogene's Dagger technology, designed to protect against immune rejection.

"The preclinical data published in Nature Communications highlight the potential of ALLO-329's dual-targeting approach to address both B- and T-cell drivers of autoimmune disease," said Zachary Roberts, the company's chief medical officer.

The Phase 1 RESOLUTION trial is currently enrolling patients with systemic lupus erythematosus, scleroderma, and inflammatory myositis. The dose-escalation study begins at 20 million CAR T cells across two groups: one receiving reduced lymphodepletion with cyclophosphamide only and another receiving no lymphodepletion.

Initial data from the first dosing group is expected in June 2026, with an additional clinical update planned later in the year. ALLO-329 received three FDA Fast Track designations in April 2025 for treating adult patients with lupus, myositis, and scleroderma.

The information is based on a company press release.